LongBio Pharma Passes HKEX Listing Hearing; Core Product LP-003 is an Anti-IgE Antibody
Newtimespace News: According to HKEX disclosure, LongBio Pharma (Suzhou) Co., Ltd. passed its main board listing hearing on May 21, 2026, with Guojin Securities (Hong Kong) Co., Ltd. acting as the sole sponsor.
Founded in 2020, LongBio Pharma is a clinical-stage biopharmaceutical company focused on the discovery and development of biologics for allergic and autoimmune diseases. The company's core product, LP-003, is an anti-IgE antibody that primarily blocks free IgE in the blood and tissues, thereby inhibiting IgE-mediated allergic reactions. It is intended for the treatment of allergic diseases, including seasonal allergic rhinitis (AR), chronic spontaneous urticaria (CSU), allergic asthma and other allergic conditions. In addition, the company also has a key product, LP-005, a bifunctional antibody fusion protein targeting complement C5 and C3b, for the treatment of related renal and hematological indications.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
